Skip to main content

Advertisement

SpringerLink
Log in

Plasma Levels of Tamoxifen, N-Desmethyl Tamoxifen and Anastrozole in a Patient with Metastatic Breast Cancer and Chronic Hemodialysis

  • Clinical Trial
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Endocrine therapy for hormone-sensitive breast cancer is a well-established treatment option, both in adjuvant and palliative settings. For patients undergoing chronic hemodialysis, only scant pharmacokinetic data have been published for tamoxifen, and no data have been published for anastrozole. We therefore measured plasma levels of tamoxifen, its major metabolite, N-desmethyl tamoxifen, and anastrozole in a breast cancer patient undergoing chronic hemodialysis. Clinical tolerability was good. The blood levels for tamoxifen, N-desmethyl tamoxifen and anastrozole were within the expected therapeutic ranges. From this study, we can conclude that endocrine therapy for breast cancer with tamoxifen or anastrozole seems feasible and safe for patients undergoing chronic hemodialysis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Morello KC, Wurz GT, DeGregorio MW (2003) Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet 42(4):362–372

    Article  Google Scholar 

  2. Bonneterre J, Buzdar A, Nabholtz JM et al (2001) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Results of two randomised trials designed for combined analysis. Cancer 92(9):2247–2258

    Article  PubMed  CAS  Google Scholar 

  3. Chem Bank (2002) Global database for potentially hazardous chemicals http://www.chembank.med.harvard.edu. Cited 22 Mar 2006

  4. Crewe HK, Noteley LM, Wunsch RM et al (2002) Metabolism of tamoxifen by recombinant human cytochrome p450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 30(8):869–874

    Article  PubMed  CAS  Google Scholar 

  5. Sheth HR, Lord G, Tkaczuk K et al (2003) Aging may be associated with concentrations of tamoxifen and its metabolites in breast cancer patients. J Womens Health (Larchmt) 2(8):799–808

    Article  Google Scholar 

  6. Guerrieri-Gonzaga A, Baglietto L, Johansson H, Bonanni B, Robertson C, Sandri MT et al (2001) Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial. Cancer Epidemiol Biomarkers Prev 10:967–970

    PubMed  CAS  Google Scholar 

  7. Sutherland CM, Sternson LA, Muchmore JH et al (1984) Effect of impaired renal function on tamoxifen. J Surg Oncol 27:222–223

    PubMed  CAS  Google Scholar 

  8. Allaria PM, Giangrande A, Gandini E et al (1999) Continuous ambulatory peritoneal dialysis and sclerosing encapsulating peritonitis: tamoxifen as a new therapeutic agent? J Nephrol 12:395–397

    PubMed  CAS  Google Scholar 

  9. Buzdar AU, Robertson JFR, Eiermann W et al (2002) An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole and exemestane. Cancer 95(9):2006–2016

    Article  PubMed  CAS  Google Scholar 

  10. Lonning P, Pfister C, Martoni A et al (2003) Pharmacokinetics of third-generation aromatase inhibitors. Sem Oncol 30(4, Supp 14):23–32

    Google Scholar 

  11. The ATAC Trialist Group (2001) Pharmacokinetics of anastrazole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the “Arimidex and Tamoxifen Alone or in Combination” (ATAC) trial. Br J Cancer 85(3):317–324

    Article  Google Scholar 

  12. Pastan S, Bailey J (1998) Dialysis therapy. NEJM 338(20):1428–1437

    Google Scholar 

  13. Remmele W, Stegner HE (1987) Vorschlag zur einheitlichen Definition eines Immunreaktiven Score (IRS) für den immunhistochemischen Östrogenrezeptor-Nachweis (ER-ICA) im Mammakarzinomgewebe. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 8:138–140

    PubMed  CAS  Google Scholar 

  14. Decensi A, Gandini S, Guerrieri-Gonzaga A (1999) Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. J Clin Oncol 17(9):2633–2638

    PubMed  CAS  Google Scholar 

  15. Fagugli RM, De Smet R, Buoncristiani U (2002) Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. Am J Kidney Dis 40(2):339–347

    Google Scholar 

Download references

Acknowledgment

This study was supported by a grant form Astra Zeneca.

Author information

Authors and Affiliations

  1. Senologiezentrum Ostschweiz, Kantonsspital St. Gallen, 9007, St. Gallen, Switzerland

    T. Langenegger & B. Thürlimann

  2. Division of Nephrology, Kantonsspital St. Gallen, St. Gallen, Switzerland

    P. Wahl & D. Schiesser

Authors
  1. T. Langenegger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Wahl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Schiesser
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Thürlimann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Langenegger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Langenegger, T., Wahl, P., Schiesser, D. et al. Plasma Levels of Tamoxifen, N-Desmethyl Tamoxifen and Anastrozole in a Patient with Metastatic Breast Cancer and Chronic Hemodialysis. Breast Cancer Res Treat 100, 177–181 (2006). https://doi.org/10.1007/s10549-006-9243-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-006-9243-7

Key words

Search

Navigation